Psychotropic Drugs and Risk of Motor Vehicle Accidents: a Population-based Case-Control Study.

Department of Psychiatry, Chang Gung Memorial Hospital, Lin-Kou & Chang Gung University, Taoyuan, Taiwan.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 09/2012; 75(4). DOI: 10.1111/j.1365-2125.2012.04410.x
Source: PubMed

ABSTRACT AIM: To comprehensively examine the relationship between exposure to four classes of psychotropic drugs including antipsychotics, antidepressants, benzodiazepines (BZDs) and Z-drugs, and motor vehicle accidents (MVAs). METHODS: The authors conducted a matched case-control study of 5,183 subjects with MVAs and 31,093 matched controls, identified from the claims records of outpatient service visits during the period from 2000 to2009. Inclusion criteria were defined as subjects aged equal to or more than 18 years and involved in MVAs. Conditional logistic regressions with covariates adjustment (including: urbanity, psychiatric and non-psychiatric outpatient visits, and Charlson comorbidity score) were applied to examine the effect of four classes of psychotropic drugs on MVAs. RESULTS: Significant increased risk of MVAs was found in subjects taking antidepressants within one month (adjusted odds ratio (AOR)=1.73, 95% confidence interval (CI)=1.34-2.22), one week (AOR=1.71, 95%CI=1.29-2.26), and one day (AOR=1.70, 95%CI=1.26-2.29) before MVAs occurred. Similar results were observed in subjects taking benzodiazepines (BZDs) (AOR=1.56, 95%CI=1.38-1.75 for one month; AOR=1.64, 95%CI=1.43-1.88 for one week, and AOR=1.62, 95%CI=1.39-1.88 for one day) and Z-drugs (AOR=1.42, 95%CI=1.14-1.76 for one month, AOR=1.37, 95%CI=1.06-1.75 for one week, AOR=1.34, 95%CI=1.03-1.75 for one day), but not antipsychotics. Moreover, significant dose effects of antidepressants (equal to or more than 0.6-1.0 DDD), BZDs (equal to or more than 0.1-0.5 DDD), and Z-drugs (more than 1 DDD) were observed, respectively, on the risk of experiencing an MVA. CONCLUSIONS: Taken together, subjects taking antidepressants, BZDs and Z-drugs, separately, should be particularly cautioned for their increasing risk of MVAs.

Download full-text


Available from: Chia-Ming Chang, Nov 22, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: This study aimed to evaluate the effects of repeated treatments with the sedative antidepressants mirtazapine and trazodone on driving performance and cognitive function. METHODS: Nineteen healthy men received continuous nocturnal doses of 15-mg mirtazapine , 25-mg trazodone, or placebo for 8 days in a double-blinded, three-way crossover trial. Subjects were asked to perform three driving tasks (road tracking, car following, and harsh braking) using a driving simulator and cognitive tasks (the Wisconsin Card Sorting Test, Continuous Performance Test, and N-back Test) at baseline and on Days 2 and 9. Stanford Sleepiness Scale scores were also assessed. RESULTS: Mirtazapine significantly increased the standard deviation of lateral position in the road-tracking task as compared with trazodone on Day 2. Mirtazapine significantly increased Stanford Sleepiness Scale scores as compared with trazodone and placebo. For the remaining tasks, no significant effects of treatment were observed. CONCLUSIONS: Acute treatment of mirtazapine impaired road-tracking performance and increased sleepiness, but sedative effects disappeared under repeated administrations. Trazodone did not affect driving performance or cognitive function under acute or repeated administrations. Both initial sedative effects and pharmacological profiles should be taken into consideration when using sedative antidepressants. Copyright © 2013 John Wiley & Sons, Ltd.
    Human Psychopharmacology Clinical and Experimental 05/2013; 28(3). DOI:10.1002/hup.2321 · 1.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dual orexin receptor antagonists (DORAs) are a potential treatment for insomnia that function by blocking both the orexin 1 and orexin 2 receptors. The objective of the current study was to further confirm the impact of therapeutic mechanisms targeting insomnia on locomotor coordination and ethanol interaction using DORAs and gamma-aminobutyric acid (GABA)-A receptor modulators of distinct chemical structure and pharmacological properties in the context of sleep-promoting potential. The current study compared rat motor co-ordination after administration of DORAs, DORA-12 and almorexant, and GABA-A receptor modulators, zolpidem, eszopiclone, and diazepam, alone or each in combination with ethanol. Motor performance was assessed by measuring time spent walking on a rotarod apparatus. Zolpidem, eszopiclone and diazepam [0.3-30 mg/kg administered orally (PO)] impaired rotarod performance in a dose-dependent manner. Furthermore, all three GABA-A receptor modulators potentiated ethanol- (0.25-1.5 g/kg) induced impairment on the rotarod. By contrast, neither DORA-12 (10-100 mg/kg, PO) nor almorexant (30-300 mg/kg, PO) impaired motor performance alone or in combination with ethanol. In addition, distinct differences in sleep architecture were observed between ethanol, GABA-A receptor modulators (zolpidem, eszopiclone, and diazepam) and DORA-12 in electroencephalogram studies in rats. These findings provide further evidence that orexin receptor antagonists have an improved motor side-effect profile compared with currently available sleep-promoting agents based on preclinical data and strengthen the rationale for further evaluation of these agents in clinical development.
    Frontiers in Neuroscience 12/2013; 7:254. DOI:10.3389/fnins.2013.00254 · 3.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Research CMAJ OPEN B enzodiazepines have been used for decades as effective agents for the treatment of seizure and anxiety disor-ders and for the short-term control of insomnia. Although their toxicology profile is favourable compared with other hypnotic drugs and sedatives, such as barbiturates, their long-term use has been associated with physiological tolerance, dependence and addiction. 1–3 Harm, supported by various levels of evidence, has been widely reported and includes higher risk of falls and fractures, 4–6 motor vehicle collisions 7 and cognitive disturbances particularly among older people. 8 Newer non-benzodiazepine agents (i.e., zopi-clone, zolpidem and zaleplon), commonly called Z-drugs, are indicated for sleep disorders. Although it has been suggested that Z-drugs have a lower potential for abuse and depen-dence, 9 their use can also be problematic because of their effects on human performance and driving. 10,11 Because of these potential adverse effects, clinical practice guidelines have advised against the use of benzodiazepines and Z-drugs for longer than 4weeks, and health agencies world-wide have undertaken anti-benzodiazepine and anti-Z-drug campaigns, not without controversy. 12–18 However, the dearth of published research studies on this subject suggests that such recommendations have not had a significant impact on the use of benzodiazepines and Z-drugs in various countries. 19–22 The only population-based study conducted in Canada was based on data from British Columbia and examined a period of 10 years between 1996 and 2006. 20 As there are long delays between the reporting of scientific knowledge and changes in clinical practice, changes in prescribing patterns may have occurred over the last 7years. Thus, in this study, we describe the prescribing patterns for benzodiazepines and Z-drugs for the entire population of a Canadian province over 16years by user characteristics.
    10/2014; DOI:10.9778/cmajo.20130076
Show more